{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:44:24Z","timestamp":1793371464481,"version":"4.5.0"},"reference-count":262,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003751","name":"Gobierno de Espana Ministerio de Sanidad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.neuropharm.2022.109211","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T19:43:04Z","timestamp":1660419784000},"page":"109211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Pharmacological strategies for post-traumatic stress disorder (PTSD): From animal to clinical studies"],"prefix":"10.1016","volume":"218","author":[{"given":"Ani","family":"Gasparyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Navarrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1251-6357","authenticated-orcid":false,"given":"Jorge","family":"Manzanares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109211_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1146\/annurev-pharmtox-010818-021701","article-title":"The neurobiology and pharmacotherapy of posttraumatic stress disorder","volume":"59","author":"Abdallah","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib2","first-page":"43","article-title":"Use of antipsychotics in the treatment of post-traumatic stress disorder","volume":"2","author":"Adetunji","year":"2005","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.neuropharm.2022.109211_bib3","series-title":"Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder","year":"2018"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/01.yic.0000182116.49887.ae","article-title":"Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study","volume":"21","author":"Ahearn","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/JCP.0000000000000638","article-title":"Prazosin in children and adolescents with posttraumatic stress disorder who have nightmares: a systematic review","volume":"37","author":"Akinsanya","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109211_bib6","series-title":"Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder","year":"2004"},{"key":"10.1016\/j.neuropharm.2022.109211_bib7","series-title":"Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults","author":"American Psychological Association APA","year":"2017"},{"issue":"11","key":"10.1016\/j.neuropharm.2022.109211_bib8","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/s41398-017-0014-5","article-title":"Fluoxetine treatment is effective in a rat model of childhood-induced post-traumatic stress disorder","volume":"7","author":"Ariel","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41398-019-0673-5","article-title":"Pharmacological prevention and early treatment of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysis","volume":"9","author":"Astill Wright","year":"2019","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5664\/jcsm.27883","article-title":"Best practice guide for the treatment of nightmare disorder in adults","volume":"6","author":"Aurora","year":"2010","journal-title":"J. Clin. Sleep Med."},{"key":"10.1016\/j.neuropharm.2022.109211_bib11","series-title":"Australian Guidelines for the Treatment of Acute Stress Disorder, Posttraumatic Stress Disorder and Complex PTSD","author":"Australian Centre for Posttraumatic Mental Health ACPMH","year":"2007"},{"key":"10.1016\/j.neuropharm.2022.109211_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107912","article-title":"The serotonergic and alpha-1 adrenergic receptor modulator ACH-000029 ameliorates anxiety-like behavior in a post-traumatic stress disorder model","volume":"164","author":"Azevedo","year":"2020","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.neuropharm.2022.109211_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/hup.426","article-title":"Effects of mirtazapine in patients with post-traumatic stress disorder in Korea: a pilot study","volume":"17","author":"Bahk","year":"2002","journal-title":"Hum. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109211_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.pra.0000456590.12998.41","article-title":"Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: a randomized controlled trial","volume":"20","author":"Baniasadi","year":"2014","journal-title":"J. Psychiatr. Pract."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109211_bib15","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.biopsych.2004.11.039","article-title":"Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder","volume":"57","author":"Bartzokis","year":"2005","journal-title":"Biol. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib16","first-page":"191","article-title":"Diagnostic and statistical manual of mental disorders (DSM)","volume":"25","author":"Battle","year":"2013","journal-title":"Codas"},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/JCP.0b013e318032eaed","article-title":"A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder","volume":"27","author":"Becker","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1017\/S0033291715001981","article-title":"The epidemiology of traumatic event exposure worldwide: results from the World Mental Health Survey Consortium","volume":"46","author":"Benjet","year":"2016","journal-title":"Psychol. Med."},{"issue":"13","key":"10.1016\/j.neuropharm.2022.109211_bib19","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00213-014-3861-2","article-title":"Effects of paroxetine on PTSD-like symptoms in mice","volume":"232","author":"Bentefour","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.euroneuro.2015.12.021","article-title":"Paroxetine treatment, following behavioral suppression of PTSD-like symptoms in mice, prevents relapse by activating the infralimbic cortex","volume":"26","author":"Bentefour","year":"2016","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2022.109211_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-244X-4-24","article-title":"Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder","volume":"4","author":"Berlant","year":"2004","journal-title":"BMC Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v63n0104","article-title":"Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report","volume":"63","author":"Berlant","year":"2002","journal-title":"J. Clin. Psychiatr."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11920-007-0035-5","article-title":"Antiepileptic drugs for the treatment of post-traumatic stress disorder","volume":"9","author":"Berlin","year":"2007","journal-title":"Curr. Psychiatr. Rep."},{"key":"10.1016\/j.neuropharm.2022.109211_bib24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.puhe.2022.05.002","article-title":"Post-traumatic stress disorder prevalence and sleep quality in fire victims and rescue workers in southern Brazil: a cross-sectional study","volume":"209","author":"Bertolazi","year":"2022","journal-title":"Publ. Health"},{"key":"10.1016\/j.neuropharm.2022.109211_bib25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF00543712","article-title":"Beta-blockers and sleep: a controlled trial","volume":"28","author":"Betts","year":"1985","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/jts.22421","article-title":"The international society for traumatic stress studies new guidelines for the prevention and treatment of posttraumatic stress disorder: methodology and development process","volume":"32","author":"Bisson","year":"2019","journal-title":"J. Trauma Stress"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1192\/bjp.2020.40","article-title":"Evidence-based prescribing for post-traumatic stress disorder","volume":"216","author":"Bisson","year":"2020","journal-title":"Br. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib28","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib29","doi-asserted-by":"crossref","first-page":"e0246990","DOI":"10.1371\/journal.pone.0246990","article-title":"The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a randomized cross-over clinical trial","volume":"16","author":"Bonn-Miller","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/02791072.2008.10400637","article-title":"MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder","volume":"40","author":"Bouso","year":"2008","journal-title":"J. Psychoact. Drugs"},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109211_bib31","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/01.pra.0000364287.63210.92","article-title":"Preliminary findings concerning the use of prazosin for the treatment of posttraumatic nightmares in a refugee population","volume":"15","author":"Boynton","year":"2009","journal-title":"J. Psychiatr. Pract."},{"issue":"5599","key":"10.1016\/j.neuropharm.2022.109211_bib32","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1126\/science.1076535","article-title":"Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling","volume":"298","author":"Bracey","year":"2002","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.neuropharm.2022.109211_bib33","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/jama.283.14.1837","article-title":"Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial","volume":"283","author":"Brady","year":"2000","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109211_bib34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11920-015-0587-8","article-title":"Treatment of sleep disturbances in post-traumatic stress disorder: a review of the literature","volume":"17","author":"Brownlow","year":"2015","journal-title":"Curr. Psychiatr. Rep."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109211_bib35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jpsychires.2007.05.006","article-title":"Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder","volume":"42","author":"Brunet","year":"2008","journal-title":"J. Psychiatr. Res."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109211_bib36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1176\/appi.ajp.2017.17050481","article-title":"Reduction of PTSD symptoms with pre-reactivation propranolol therapy: a randomized controlled trial","volume":"175","author":"Brunet","year":"2018","journal-title":"Am. J. Psychiatr."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/JCP.0b013e3181dac52f","article-title":"Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety","volume":"30","author":"Byers","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6499","key":"10.1016\/j.neuropharm.2022.109211_bib38","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/371702a0","article-title":"Beta-adrenergic activation and memory for emotional events","volume":"371","author":"Cahill","year":"1994","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109211_bib39","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/JCP.0000000000000180","article-title":"Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation","volume":"34","author":"Cameron","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.neuropharm.2022.109211_bib40","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jpsychires.2012.08.012","article-title":"Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors","volume":"46","author":"Campos","year":"2012","journal-title":"J. Psychiatr. Res."},{"issue":"9","key":"10.1016\/j.neuropharm.2022.109211_bib41","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1345\/aph.1E043","article-title":"Clonazepam for treatment of sleep disturbances associated with combat-related posttraumatic stress disorder","volume":"38","author":"Cates","year":"2004","journal-title":"Ann. Pharmacother."},{"issue":"7","key":"10.1016\/j.neuropharm.2022.109211_bib42","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/hup.615","article-title":"Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial","volume":"19","author":"Chung","year":"2004","journal-title":"Hum. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109211_bib43","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1017\/S003329171700349X","article-title":"Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis","volume":"48","author":"Cipriani","year":"2018","journal-title":"Psychol. Med."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1023\/A:1024797014210","article-title":"Divalproex in posttraumatic stress disorder: an open-label clinical trial","volume":"12","author":"Clark","year":"1999","journal-title":"J. Trauma Stress"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib45","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.euroneuro.2010.11.011","article-title":"Early post-stressor intervention with propranolol is ineffective in preventing posttraumatic stress responses in an animal model for PTSD","volume":"21","author":"Cohen","year":"2011","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2022.109211_bib46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1192\/bjp.175.1.17","article-title":"Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study","volume":"175","author":"Connor","year":"1999","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004850-199901000-00003","article-title":"A pilot study of mirtazapine in post-traumatic stress disorder","volume":"14","author":"Connor","year":"1999","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00213-005-0265-3","article-title":"Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment","volume":"184","author":"Connor","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"10.1016\/j.neuropharm.2022.109211_bib49","doi-asserted-by":"crossref","first-page":"e1003262","DOI":"10.1371\/journal.pmed.1003262","article-title":"Psychological and pharmacological interventions for posttraumatic stress disorder and comorbid mental health problems following complex traumatic events: systematic review and component network meta-analysis","volume":"17","author":"Coventry","year":"2020","journal-title":"PLoS Med."},{"issue":"6604","key":"10.1016\/j.neuropharm.2022.109211_bib50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/384083a0","article-title":"Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides","volume":"384","author":"Cravatt","year":"1996","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.neuropharm.2022.109211_bib51","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1017\/S0033291701004287","article-title":"Post-traumatic stress disorder: findings from the Australian national survey of mental health and well-being","volume":"31","author":"Creamer","year":"2001","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2022.109211_bib52","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cpr.2015.10.003","article-title":"Psychological treatments for adults with posttraumatic stress disorder: a systematic review and meta-analysis","volume":"43","author":"Cusack","year":"2016","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.neuropharm.2022.109211_bib53","article-title":"Low dose ketamine infusion for comorbid posttraumatic stress disorder and chronic pain: a randomized double-blind clinical trial","volume":"4","author":"Dadabayev","year":"2020","journal-title":"Chronic Stress (Thousand Oaks)"},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib54","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00004850-200403000-00005","article-title":"Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson trauma scale, clinical global impressions and the clinician-administered PTSD scale","volume":"19","author":"Davidson","year":"2004","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109211_bib55","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1176\/appi.ajp.158.12.1974","article-title":"Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study","volume":"158","author":"Davidson","year":"2001","journal-title":"Am. J. Psychiatr."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109211_bib56","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1001\/archpsyc.58.5.485","article-title":"Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder","volume":"58","author":"Davidson","year":"2001","journal-title":"Arch. Gen. Psychiatr."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib57","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1017\/S0033291702005469","article-title":"Characterizing the effects of sertraline in post-traumatic stress disorder","volume":"32","author":"Davidson","year":"2002","journal-title":"Psychol. Med."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib58","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0006-3223(02)01411-7","article-title":"Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial","volume":"53","author":"Davidson","year":"2003","journal-title":"Biol. Psychiatr."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib59","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.jcp.0000222514.71390.c1","article-title":"Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study","volume":"26","author":"Davidson","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.neuropharm.2022.109211_bib60","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1001\/archpsyc.63.10.1158","article-title":"Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial","volume":"63","author":"Davidson","year":"2006","journal-title":"Arch. Gen. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/JCP.0b013e31802e5115","article-title":"The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder","volume":"27","author":"Davidson","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/JCP.0b013e318160f83b","article-title":"Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population","volume":"28","author":"Davis","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib63","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jpsychires.2006.11.009","article-title":"Elevated plasma arginine vasopressin levels in veterans with posttraumatic stress disorder","volume":"42","author":"de Kloet","year":"2008","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2022.109211_bib64","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jpsychires.2020.07.046","article-title":"Pharmacological treatments for adults with post-traumatic stress disorder: a network meta-analysis of comparative efficacy and acceptability","volume":"130","author":"de Moraes Costa","year":"2020","journal-title":"J. Psychiatr. Res."},{"issue":"15","key":"10.1016\/j.neuropharm.2022.109211_bib65","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2165\/00003088-200241150-00002","article-title":"Clinical pharmacokinetics of sertraline","volume":"41","author":"DeVane","year":"2002","journal-title":"Clin. Pharmacokinet."},{"issue":"16","key":"10.1016\/j.neuropharm.2022.109211_bib66","doi-asserted-by":"crossref","first-page":"10819","DOI":"10.1073\/pnas.152334899","article-title":"Brain monoglyceride lipase participating in endocannabinoid inactivation","volume":"99","author":"Dinh","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.neuropharm.2022.109211_bib67","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.4088\/JCP.v65n1120","article-title":"Treatment of posttraumatic stress disorder with phenytoin: an open-label pilot study","volume":"65","author":"Douglas Bremner","year":"2004","journal-title":"J. Clin. Psychiatr."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib68","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S2215-0366(16)30377-7","article-title":"Post-traumatic stress disorder and cardiovascular disease","volume":"4","author":"Edmondson","year":"2017","journal-title":"Lancet Psychiatr."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib69","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1089\/acm.2018.0437","article-title":"Cannabidiol in the treatment of post-traumatic stress disorder: a case series","volume":"25","author":"Elms","year":"2019","journal-title":"J. Alternative Compl. Med."},{"key":"10.1016\/j.neuropharm.2022.109211_bib70","first-page":"229","article-title":"The complexity of pharmacology of cannabidiol (CBD) and its implications in the treatment of brain disorders","volume":"45 (1)","author":"Elsaid","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109211_bib71","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","article-title":"Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial","volume":"71","author":"Feder","year":"2014","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109211_bib72","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/bs.apha.2020.05.004","article-title":"The emergence of ketamine as a novel treatment for posttraumatic stress disorder","volume":"89","author":"Feder","year":"2020","journal-title":"Adv. Pharmacol."},{"issue":"9","key":"10.1016\/j.neuropharm.2022.109211_bib73","first-page":"361","article-title":"Valproate in combat-related posttraumatic stress disorder","volume":"52","author":"Fesler","year":"1991","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109211_bib74","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jpsychires.2017.12.014","article-title":"Augmenting Prolonged Exposure therapy for PTSD with intranasal oxytocin: a randomized, placebo-controlled pilot trial","volume":"98","author":"Flanagan","year":"2018","journal-title":"J. Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib75","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1037\/pha0000197","article-title":"Effects of oxytocin on working memory and executive control system connectivity in posttraumatic stress disorder","volume":"26","author":"Flanagan","year":"2018","journal-title":"Exp. Clin. Psychopharmacol"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib76","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1037\/pha0000232","article-title":"Effects of oxytocin on stress reactivity and craving in veterans with co-occurring PTSD and alcohol use disorder","volume":"27","author":"Flanagan","year":"2019","journal-title":"Exp. Clin. Psychopharmacol"},{"key":"10.1016\/j.neuropharm.2022.109211_bib77","series-title":"Psychological and Pharmacological Treatments for Adults with Posttraumatic Stress Disorder: A Systematic Review Update","author":"Forman-Hoffman","year":"2018"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib78","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1755-5949.2008.00071.x","article-title":"The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD)","volume":"15","author":"Fraser","year":"2009","journal-title":"CNS Neurosci. Ther."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109211_bib79","doi-asserted-by":"crossref","first-page":"711","DOI":"10.4088\/JCP.v68n0508","article-title":"Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting","volume":"68","author":"Friedman","year":"2007","journal-title":"J. Clin. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib80","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12031-015-0532-7","article-title":"Risperidone attenuates modified stress-Re-stress paradigm-induced mitochondrial dysfunction and apoptosis in rats exhibiting post-traumatic stress disorder-like symptoms","volume":"56","author":"Garabadu","year":"2015","journal-title":"J. Mol. Neurosci."},{"issue":"11","key":"10.1016\/j.neuropharm.2022.109211_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/biom10111575","article-title":"Cannabidiol: a potential new alternative for the treatment of anxiety, depression, and psychotic disorders","volume":"10","author":"Garcia-Gutierrez","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuropharm.2022.109211_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.694510","article-title":"Cannabidiol and sertraline regulate behavioral and brain gene expression alterations in an animal model of PTSD","volume":"12","author":"Gasparyan","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.neuropharm.2022.109211_bib83","first-page":"390","article-title":"Treatment of recent trauma survivors with benzodiazepines: a prospective study","volume":"57","author":"Gelpin","year":"1996","journal-title":"J. Clin. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib84","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpsychores.2011.11.010","article-title":"Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US Military Veterans","volume":"72","author":"Germain","year":"2012","journal-title":"J. Psychosom. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2022.109211_bib85","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/j.1528-1157.2000.tb02164.x","article-title":"Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons","volume":"41","author":"Gibbs","year":"2000","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.neuropharm.2022.109211_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9113492","article-title":"An emulation of randomized trials of administrating benzodiazepines in PTSD patients for outcomes of suicide-related events","volume":"9","author":"Gilbert","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.neuropharm.2022.109211_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2016.12.026","article-title":"Ketamine accelerates fear extinction via mTORC1 signaling","volume":"100","author":"Girgenti","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2022.109211_bib88","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.nlm.2016.01.009","article-title":"Revisiting propranolol and PTSD: memory erasure or extinction enhancement?","volume":"130","author":"Giustino","year":"2016","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.neuropharm.2022.109211_bib89","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fnins.2013.00089","article-title":"Animal models of post-traumatic stress disorder: face validity","volume":"7","author":"Goswami","year":"2013","journal-title":"Front. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib90","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/01.pra.0000452561.98286.1e","article-title":"Prazosin in the treatment of PTSD","volume":"20","author":"Green","year":"2014","journal-title":"J. Psychiatr. Pract."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib91","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/02791072.2013.873843","article-title":"PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program","volume":"46","author":"Greer","year":"2014","journal-title":"J. Psychoact. Drugs"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib92","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/PRA.0000000000000091","article-title":"Benzodiazepines for PTSD: a systematic review and meta-analysis","volume":"21","author":"Guina","year":"2015","journal-title":"J. Psychiatr. Pract."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib93","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1460-9568.2004.03428.x","article-title":"Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala","volume":"20","author":"Gulyas","year":"2004","journal-title":"Eur. J. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib94","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/10401230109148960","article-title":"Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy","volume":"13","author":"Hamner","year":"2001","journal-title":"Ann. Clin. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib95","first-page":"1","article-title":"Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms","volume":"18","author":"Hamner","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib96","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00004714-200302000-00003","article-title":"Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy","volume":"23","author":"Hamner","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib97","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/104012370902100205","article-title":"A preliminary controlled trial of divalproex in posttraumatic stress disorder","volume":"21","author":"Hamner","year":"2009","journal-title":"Ann. Clin. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib98","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/JCP.0000000000001000","article-title":"Ziprasidone augmentation of SSRI antidepressants in posttraumatic stress disorder: a randomized, placebo-controlled pilot study of augmentation therapy","volume":"39","author":"Hamner","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib99","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.pscychresns.2015.02.011","article-title":"Effects of fluoxetine on the amygdala and the hippocampus after administration of a single prolonged stress to male Wistar rates: in vivo proton magnetic resonance spectroscopy findings","volume":"232","author":"Han","year":"2015","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2022.109211_bib100","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s00213-022-06132-6","article-title":"Comparison between cannabidiol and sertraline for the modulation of post-traumatic stress disorder-like behaviors and fear memory in mice","volume":"239 (5)","author":"Han","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"10.1016\/j.neuropharm.2022.109211_bib101","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0006-3223(99)00011-6","article-title":"A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder","volume":"45","author":"Hertzberg","year":"1999","journal-title":"Biol. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib102","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/10401230009147096","article-title":"Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans","volume":"12","author":"Hertzberg","year":"2000","journal-title":"Ann. Clin. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib103","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1755-5949.2010.00227.x","article-title":"Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery","volume":"18","author":"Hoge","year":"2012","journal-title":"CNS Neurosci. Ther."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib104","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1192\/bjp.bp.114.148551","article-title":"Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis","volume":"206","author":"Hoskins","year":"2015","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib105","article-title":"Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches","volume":"12","author":"Hoskins","year":"2021","journal-title":"Eur. J. Psychotraumatol."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib106","article-title":"Pharmacological-assisted psychotherapy for post-traumatic stress disorder: a systematic review and meta-analysis","volume":"12","author":"Hoskins","year":"2021","journal-title":"Eur. J. Psychotraumatol."},{"key":"10.1016\/j.neuropharm.2022.109211_bib107","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3389\/fphar.2020.00559","article-title":"Comparative efficacy and acceptability of pharmaceutical management for adults with post-traumatic stress disorder: a systematic review and meta-analysis","volume":"11","author":"Huang","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.neuropharm.2022.109211_bib108","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s00213-020-05548-2","article-title":"Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials","volume":"237","author":"Jerome","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109211_bib109","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","article-title":"The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study","volume":"51","author":"Jetly","year":"2015","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib110","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s12888-016-1138-5","article-title":"Dosage, effectiveness, and safety of sertraline treatment for posttraumatic stress disorder in a Japanese clinical setting: a retrospective study","volume":"16","author":"Kamo","year":"2016","journal-title":"BMC Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib111","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/da.22169","article-title":"Cumulative traumas and risk thresholds: 12-month PTSD in the World Mental Health (WMH) surveys","volume":"31","author":"Karam","year":"2014","journal-title":"Depress. Anxiety"},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109211_bib112","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/archpsyc.1995.03950240066012","article-title":"Posttraumatic stress disorder in the national comorbidity survey","volume":"52","author":"Kessler","year":"1995","journal-title":"Arch. Gen. Psychiatr."},{"issue":"Suppl. 5","key":"10.1016\/j.neuropharm.2022.109211_bib113","article-title":"Trauma and PTSD in the WHO World mental health surveys","volume":"8","author":"Kessler","year":"2017","journal-title":"Eur. J. Psychotraumatol."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib114","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/wps.20971","article-title":"Patterns and correlates of patient-reported helpfulness of treatment for common mental and substance use disorders in the WHO World Mental Health Surveys","volume":"21","author":"Kessler","year":"2022","journal-title":"World Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109211_bib115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.genhosppsych.2015.10.007","article-title":"Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: a systematic review and meta-analysis of randomized controlled trials","volume":"39","author":"Khachatryan","year":"2016","journal-title":"Gen. Hosp. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib116","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00213-003-1634-4","article-title":"Topiramate attenuates exaggerated acoustic startle in an animal model of PTSD","volume":"172","author":"Khan","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib117","doi-asserted-by":"crossref","first-page":"e2603","DOI":"10.17795\/ijpbs-2603","article-title":"Prazosin for trauma nightmares and sleep disturbances in combat veterans with post-traumatic stress disorder","volume":"10","author":"Khazaie","year":"2016","journal-title":"Iran J Psychiatry Behav Sci"},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109211_bib118","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1440-1819.2005.01447.x","article-title":"The effectiveness of mirtazapine in the treatment of post-traumatic stress disorder: a 24-week continuation therapy","volume":"59","author":"Kim","year":"2005","journal-title":"Psychiatr. Clin. Neurosci."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109211_bib119","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1440-1819.2008.01862.x","article-title":"Clinical evaluation of paroxetine in post-traumatic stress disorder (PTSD): 52-week, non-comparative open-label study for clinical use experience","volume":"62","author":"Kim","year":"2008","journal-title":"Psychiatr. Clin. Neurosci."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109211_bib120","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11920-018-0981-0","article-title":"Chromosomes to social contexts: sex and gender differences in PTSD","volume":"20","author":"Kimerling","year":"2018","journal-title":"Curr. Psychiatr. Rep."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib121","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4088\/JCP.v67n0206","article-title":"Levetiracetam for treatment-refractory posttraumatic stress disorder","volume":"67","author":"Kinrys","year":"2006","journal-title":"J. Clin. Psychiatr."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib122","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1176\/ajp.151.4.621a","article-title":"Sertraline efficacy in depressed combat veterans with posttraumatic stress disorder","volume":"151","author":"Kline","year":"1994","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109211_bib123","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.psyneuen.2013.11.018","article-title":"Intranasal oxytocin as strategy for medication-enhanced psychotherapy of PTSD: salience processing and fear inhibition processes","volume":"40","author":"Koch","year":"2014","journal-title":"Psychoneuroendocrinology"},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109211_bib124","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/npp.2015.299","article-title":"Intranasal oxytocin administration dampens amygdala reactivity towards emotional faces in male and female PTSD patients","volume":"41","author":"Koch","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109211_bib125","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00005053-199106000-00011","article-title":"Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine","volume":"179","author":"Kosten","year":"1991","journal-title":"J. Nerv. Ment. Dis."},{"issue":"7","key":"10.1016\/j.neuropharm.2022.109211_bib126","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/00005053-200007000-00010","article-title":"Benzodiazepine use in posttraumatic stress disorder among veterans with substance abuse","volume":"188","author":"Kosten","year":"2000","journal-title":"J. Nerv. Ment. Dis."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib127","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041662","article-title":"Paroxetine-Overview of the molecular mechanisms of action","volume":"22","author":"Kowalska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib128","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1017\/S1461145706006596","article-title":"Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features","volume":"10","author":"Kozaric-Kovacic","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2022.109211_bib129","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4088\/JCP.v66n0716","article-title":"Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial","volume":"66","author":"Kozaric-Kovacic","year":"2005","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109211_bib130","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neuropharm.2013.07.005","article-title":"Risperidone ameliorates post-traumatic stress disorder-like symptoms in modified stress re-stress model","volume":"75","author":"Krishnamurthy","year":"2013","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109211_bib131","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jama.2011.1080","article-title":"Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial","volume":"306","author":"Krystal","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib132","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4088\/JCP.14m09585","article-title":"Sleep disturbance in chronic military-related PTSD: clinical impact and response to adjunctive risperidone in the Veterans Affairs cooperative study #504","volume":"77","author":"Krystal","year":"2016","journal-title":"J. Clin. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib133","doi-asserted-by":"crossref","first-page":"76","DOI":"10.17305\/bjbms.2008.3002","article-title":"Paroxetine in the treatment of post traumatic stress disorder: our experiences","volume":"8","author":"Kucukalic","year":"2008","journal-title":"Bosn. J. Basic Med. Sci."},{"issue":"9","key":"10.1016\/j.neuropharm.2022.109211_bib134","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.mayocp.2012.05.015","article-title":"Treatment of nightmares with prazosin: a systematic review","volume":"87","author":"Kung","year":"2012","journal-title":"Mayo Clin. Proc."},{"issue":"9","key":"10.1016\/j.neuropharm.2022.109211_bib135","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s00213-021-05861-4","article-title":"The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study","volume":"238","author":"Lago","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib136","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/187152706776359664","article-title":"The involvement of the vasopressin system in stress-related disorders","volume":"5","author":"Landgraf","year":"2006","journal-title":"CNS Neurol. Disord.: Drug Targets"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib137","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.biopsych.2015.05.003","article-title":"Intranasal oxytocin: myths and delusions","volume":"79","author":"Leng","year":"2016","journal-title":"Biol. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib138","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.pbb.2006.08.015","article-title":"The effects of chronic valproate and diazepam in a mouse model of posttraumatic stress disorder","volume":"85","author":"Li","year":"2006","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109211_bib139","article-title":"Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling","volume":"145","author":"Liechti","year":"2015","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.neuropharm.2022.109211_bib140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbr.2018.12.051","article-title":"Subchronic administration of aripiprazole improves fear extinction retrieval of Pavlovian conditioning paradigm in rats experiencing psychological trauma","volume":"362","author":"Lin","year":"2019","journal-title":"Behav. Brain Res."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109211_bib141","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/jcp.0b013e31815a43ee","article-title":"A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder","volume":"27","author":"Lindley","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib142","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/hup.2522","article-title":"Pharmacology for sleep disturbance in PTSD","volume":"31","author":"Lipinska","year":"2016","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109211_bib143","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212305","article-title":"Ketamine as treatment for post-traumatic stress disorder: a review","volume":"8","author":"Liriano","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.neuropharm.2022.109211_bib144","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jad.2015.11.051","article-title":"Propranolol's impact on cognitive performance in post-traumatic stress disorder","volume":"192","author":"Mahabir","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109211_bib145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2017.08.001","article-title":"Antidepressant-like activity of venlafaxine and clonidine in mice exposed to single prolonged stress - a model of post-traumatic stress disorder. Pharmacodynamic and molecular docking studies","volume":"1673","author":"Malikowska","year":"2017","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib146","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.pbb.2007.01.019","article-title":"Prazosin administered prior to inescapable stressor blocks subsequent exaggeration of acoustic startle response in rats","volume":"86","author":"Manion","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109211_bib147","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1176\/appi.ajp.158.12.1982","article-title":"Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study","volume":"158","author":"Marshall","year":"2001","journal-title":"Am. J. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib148","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/da.20176","article-title":"A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults","volume":"24","author":"Marshall","year":"2007","journal-title":"Depress. Anxiety"},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109211_bib149","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.euroneuro.2005.10.007","article-title":"Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: analysis of the veteran group of a placebo-controlled, randomized clinical trial","volume":"16","author":"Martenyi","year":"2006","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2022.109211_bib150","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1192\/bjp.181.4.315","article-title":"Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder","volume":"181","author":"Martenyi","year":"2002","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib151","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4088\/JCP.v63n0305","article-title":"Fluoxetine versus placebo in posttraumatic stress disorder","volume":"63","author":"Martenyi","year":"2002","journal-title":"J. Clin. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib152","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/JCP.0b013e31803308ce","article-title":"Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study","volume":"27","author":"Martenyi","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"issue":"18","key":"10.1016\/j.neuropharm.2022.109211_bib153","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10184175","article-title":"Treatment guidelines for PTSD: a systematic review","volume":"10","author":"Martin","year":"2021","journal-title":"J. Clin. Med."},{"issue":"11","key":"10.1016\/j.neuropharm.2022.109211_bib154","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.biopsych.2013.08.024","article-title":"Angiotensin type 1 receptor inhibition enhances the extinction of fear memory","volume":"75","author":"Marvar","year":"2014","journal-title":"Biol. Psychiatr."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109211_bib155","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/sj.npp.1301132","article-title":"The effect of early poststressor intervention with sertraline on behavioral responses in an animal model of post-traumatic stress disorder","volume":"31","author":"Matar","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib156","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.euroneuro.2008.12.004","article-title":"Alprazolam treatment immediately after stress exposure interferes with the normal HPA-stress response and increases vulnerability to subsequent stress in an animal model of PTSD","volume":"19","author":"Matar","year":"2009","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109211_bib157","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/JCP.0000000000000968","article-title":"A pilot, randomized clinical trial of bedtime doses of prazosin versus placebo in suicidal posttraumatic stress disorder patients with nightmares","volume":"38","author":"McCall","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib158","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/19390211.2019.1572040","article-title":"Comparing perika st. John's Wort and sertraline for treatment of posttraumatic stress disorder in mice","volume":"17","author":"McFadden","year":"2020","journal-title":"J. Diet. Suppl."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib159","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1590\/S1516-44462008000400011","article-title":"Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial","volume":"30","author":"Mello","year":"2008","journal-title":"Braz J Psychiatry"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib160","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00004850-200015040-00006","article-title":"Symptom-specific effects of fluoxetine in post-traumatic stress disorder","volume":"15","author":"Meltzer-Brody","year":"2000","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.neuropharm.2022.109211_bib161","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/jamapsychiatry.2019.0951","article-title":"Comparative efficacy and acceptability of pharmacological, psychotherapeutic, and combination treatments in adults with posttraumatic stress disorder: a network meta-analysis","volume":"76","author":"Merz","year":"2019","journal-title":"JAMA Psychiatr."},{"issue":"7","key":"10.1016\/j.neuropharm.2022.109211_bib162","doi-asserted-by":"crossref","first-page":"e101450","DOI":"10.1371\/journal.pone.0101450","article-title":"Midazolam ameliorates the behavior deficits of a rat posttraumatic stress disorder model through dual 18 kDa translocator protein and central benzodiazepine receptor and neurosteroidogenesis","volume":"9","author":"Miao","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib163","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of {+\/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study","volume":"25","author":"Mithoefer","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib164","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0269881112456611","article-title":"Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study","volume":"27","author":"Mithoefer","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109211_bib165","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer","year":"2018","journal-title":"Lancet Psychiatr."},{"issue":"9","key":"10.1016\/j.neuropharm.2022.109211_bib166","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","article-title":"MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials","volume":"236","author":"Mithoefer","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib167","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m13038","article-title":"Impact of concurrent posttraumatic stress disorder on outcomes of antipsychotic augmentation for major depressive disorder with a prior failed treatment: VAST-D randomized clinical trial","volume":"81","author":"Mohamed","year":"2020","journal-title":"J. Clin. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib168","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00004714-200304000-00012","article-title":"Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder","volume":"23","author":"Monnelly","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib169","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cpr.2014.03.002","article-title":"Remission from post-traumatic stress disorder in adults: a systematic review and meta-analysis of long term outcome studies","volume":"34","author":"Morina","year":"2014","journal-title":"Clin. Psychol. Rev."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib170","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.neuropharm.2011.02.029","article-title":"Treating nightmares and insomnia in posttraumatic stress disorder: a review of current evidence","volume":"62","author":"Nappi","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109211_bib171","series-title":"Post-Traumatic Stress Disorder (PTSD). NICE Guideline [NG116]","year":"2018"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib172","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/YIC.0000000000000061","article-title":"A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment","volume":"30","author":"Naylor","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109211_bib173","doi-asserted-by":"crossref","first-page":"e8472","DOI":"10.7717\/peerj.8472","article-title":"Effects of chronic prazosin, an alpha-1 adrenergic antagonist, on anxiety-like behavior and cortisol levels in a chronic unpredictable stress model in zebrafish (Danio rerio)","volume":"8","author":"O'Daniel","year":"2020","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib174","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/0269881112464827","article-title":"A randomized, controlled pilot study of MDMA (+\/- 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)","volume":"27","author":"Oehen","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109211_bib175","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00004850-200609000-00005","article-title":"Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women","volume":"21","author":"Padala","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2022.109211_bib176","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/j.apsb.2021.01.014","article-title":"Intranasal temperature-sensitive hydrogels of cannabidiol inclusion complex for the treatment of post-traumatic stress disorder","volume":"11","author":"Pang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib177","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41398-019-0371-3","article-title":"Chronic fluoxetine prevents fear memory generalization and enhances subsequent extinction by remodeling hippocampal dendritic spines and slowing down systems consolidation","volume":"9","author":"Pedraza","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109211_bib178","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.bbr.2016.01.056","article-title":"Severe, multimodal stress exposure induces PTSD-like characteristics in a mouse model of single prolonged stress","volume":"303","author":"Perrine","year":"2016","journal-title":"Behav. Brain Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib179","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"14","key":"10.1016\/j.neuropharm.2022.109211_bib180","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2174\/092986710790980050","article-title":"Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists","volume":"17","author":"Pertwee","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2022.109211_bib181","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-20825-1_1","article-title":"Endocannabinoids and their pharmacological actions","volume":"231","author":"Pertwee","year":"2015","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109211_bib182","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bbr.2014.11.006","article-title":"The CRF(1) receptor antagonist SSR125543 prevents stress-induced long-lasting sleep disturbances in a mouse model of PTSD: comparison with paroxetine and d-cycloserine","volume":"279","author":"Philbert","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109211_bib183","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jbtep.2015.01.002","article-title":"Prolonged exposure, paroxetine and the combination in the treatment of PTSD following a motor vehicle accident. A randomized clinical trial - the \"TRAKT\" study","volume":"48","author":"Popiel","year":"2015","journal-title":"J. Behav. Ther. Exp. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib184","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/B:NERE.0000010456.92887.3b","article-title":"Modulation by topiramate of AMPA and kainate mediated calcium influx in cultured cerebral cortical, hippocampal and cerebellar neurons","volume":"29","author":"Poulsen","year":"2004","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2022.109211_bib185","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bbi.2015.10.017","article-title":"Candesartan ameliorates impaired fear extinction induced by innate immune activation","volume":"52","author":"Quinones","year":"2016","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib186","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41398-018-0310-8","article-title":"Enhanced fear memories and brain glucose metabolism ((18)F-FDG-PET) following sub-anesthetic intravenous ketamine infusion in Sprague-Dawley rats","volume":"8","author":"Radford","year":"2018","journal-title":"Transl. Psychiatry"},{"issue":"7","key":"10.1016\/j.neuropharm.2022.109211_bib187","doi-asserted-by":"crossref","first-page":"565","DOI":"10.4088\/JCP.v63n0705","article-title":"Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder","volume":"63","author":"Raskind","year":"2002","journal-title":"J. Clin. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib188","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1176\/appi.ajp.160.2.371","article-title":"Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study","volume":"160","author":"Raskind","year":"2003","journal-title":"Am. J. Psychiatr."},{"issue":"8","key":"10.1016\/j.neuropharm.2022.109211_bib189","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.biopsych.2006.06.032","article-title":"A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder","volume":"61","author":"Raskind","year":"2007","journal-title":"Biol. Psychiatr."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109211_bib190","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1507598","article-title":"Trial of prazosin for post-traumatic stress disorder in military veterans","volume":"378","author":"Raskind","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib191","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/jamapsychiatry.2018.3412","article-title":"Efficacy of prolonged exposure therapy, sertraline hydrochloride, and their combination among combat veterans with posttraumatic stress disorder: a randomized clinical trial","volume":"76","author":"Rauch","year":"2019","journal-title":"JAMA Psychiatr."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109211_bib192","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.4088\/JCP.v65n1204","article-title":"A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women","volume":"65","author":"Reich","year":"2004","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109211_bib193","series-title":"Prazosin for Treatment of Post-traumatic Stress Disorder: a Systematic Review and Meta-Analysis","first-page":"1","author":"Reist","year":"2020"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib194","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/JCP.0000000000000624","article-title":"Effect of rivastigmine augmentation in treatment of male patients with combat-related chronic posttraumatic stress disorder: a randomized controlled trial","volume":"37","author":"Rezaei Ardani","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.neuropharm.2022.109211_bib195","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41380-018-0272-5","article-title":"Animal models of PTSD: a challenge to be met","volume":"24","author":"Richter-Levin","year":"2019","journal-title":"Mol. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib196","first-page":"69","article-title":"An open-label assessment of aripiprazole in the treatment of PTSD","volume":"42","author":"Robert","year":"2009","journal-title":"Psychopharmacol. Bull."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109211_bib197","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1176\/ajp.146.6.697","article-title":"Sleep disturbance as the hallmark of posttraumatic stress disorder","volume":"146","author":"Ross","year":"1989","journal-title":"Am. J. Psychiatr."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib198","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/154733251903100411","article-title":"High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans","volume":"31","author":"Ross","year":"2019","journal-title":"Ann. Clin. Psychiatr."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109211_bib199","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/jts.20170","article-title":"Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder","volume":"19","author":"Rothbaum","year":"2006","journal-title":"J. Trauma Stress"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib200","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4088\/JCP.v69n0402","article-title":"Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder","volume":"69","author":"Rothbaum","year":"2008","journal-title":"J. Clin. Psychiatr."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109211_bib201","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1176\/appi.ajp.2014.13121625","article-title":"A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans","volume":"171","author":"Rothbaum","year":"2014","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109211_bib202","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107402","article-title":"Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders","volume":"204","author":"Sartori","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109211_bib203","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.neulet.2017.08.026","article-title":"Ketamine promotes increased freezing behavior in rats with experimental PTSD without changing brain glucose metabolism or BDNF","volume":"658","author":"Saur","year":"2017","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib204","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.neulet.2003.12.039","article-title":"Effect of paroxetine on a model of posttraumatic stress disorder in rats","volume":"357","author":"Sawamura","year":"2004","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib205","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1176\/appi.ajp.2011.11020321","article-title":"Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial","volume":"169","author":"Schneier","year":"2012","journal-title":"Am. J. Psychiatr."},{"issue":"8","key":"10.1016\/j.neuropharm.2022.109211_bib206","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/da.22384","article-title":"Combined mirtazapine and ssri treatment of ptsd: a placebo-controlled trial","volume":"32","author":"Schneier","year":"2015","journal-title":"Depress. Anxiety"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib207","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41386-020-00923-1","article-title":"The renin-angiotensin system in PTSD: a replication and extension","volume":"46","author":"Seligowski","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109211_bib208","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.nlm.2017.01.009","volume":"139","author":"Shafia","year":"2017","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.neuropharm.2022.109211_bib209","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fnbeh.2019.00091","article-title":"The divergent effects of CDPPB and cannabidiol on fear extinction and anxiety in a predator scent stress model of PTSD in rats","volume":"13","author":"Shallcross","year":"2019","journal-title":"Front. Behav. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib210","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7812\/TPP\/16-005","article-title":"Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report","volume":"20","author":"Shannon","year":"2016","journal-title":"Perm. J."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib211","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0165-1781(88)90057-1","article-title":"A controlled trial of phenelzine in posttraumatic stress disorder","volume":"24","author":"Shestatzky","year":"1988","journal-title":"Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib212","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41386-019-0553-y","article-title":"Angiotensin involvement in trauma processing-exploring candidate neurocognitive mechanisms of preventing post-traumatic stress symptoms","volume":"45","author":"Shkreli","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib213","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4088\/JCP.v69n0309","article-title":"Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy","volume":"69","author":"Simon","year":"2008","journal-title":"J. Clin. Psychiatr."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib214","article-title":"Efficacy of prazosin in posttraumatic stress disorder: a systematic review and meta-analysis","volume":"18","author":"Singh","year":"2016","journal-title":"Prim Care Companion CNS Disord"},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109211_bib215","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1080\/10253890.2020.1826430","article-title":"Vasopressin and post-traumatic stress disorder","volume":"23","author":"Sipos","year":"2020","journal-title":"Stress"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib216","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1023\/A:1011177420069","article-title":"Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms","volume":"14","author":"Smajkic","year":"2001","journal-title":"J. Trauma Stress"},{"key":"10.1016\/j.neuropharm.2022.109211_bib217","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.psyneuen.2015.09.017","article-title":"Local oxytocin tempers anxiety by activating GABAA receptors in the hypothalamic paraventricular nucleus","volume":"63","author":"Smith","year":"2016","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib218","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12888-016-1081-5","article-title":"Treatment of trauma-affected refugees with venlafaxine versus sertraline combined with psychotherapy - a randomised study","volume":"16","author":"Sonne","year":"2016","journal-title":"BMC Psychiatr."},{"issue":"9","key":"10.1016\/j.neuropharm.2022.109211_bib219","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0006-3223(99)00219-X","article-title":"Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder","volume":"46","author":"Southwick","year":"1999","journal-title":"Biol. Psychiatr."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib220","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0165-0327(98)00221-3","article-title":"Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects","volume":"51","author":"Stahl","year":"1998","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109211_bib221","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/jama.2015.8370","article-title":"Psychotherapy for military-related PTSD: a review of randomized clinical trials","volume":"314","author":"Steenkamp","year":"2015","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.neuropharm.2022.109211_bib222","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.biopsych.2021.05.012","article-title":"Randomized, placebo-controlled trial of the angiotensin receptor antagonist losartan for posttraumatic stress disorder","volume":"90","author":"Stein","year":"2021","journal-title":"Biol. Psychiatr."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib223","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10578-007-0055-8","article-title":"Divalproex sodium for the treatment of PTSD and conduct disordered youth: a pilot randomized controlled clinical trial","volume":"38","author":"Steiner","year":"2007","journal-title":"Child Psychiatr. Hum. Dev."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109211_bib224","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.brs.2013.05.008","article-title":"Amygdala deep brain stimulation is superior to paroxetine treatment in a rat model of posttraumatic stress disorder","volume":"6","author":"Stidd","year":"2013","journal-title":"Brain Stimul."},{"issue":"21","key":"10.1016\/j.neuropharm.2022.109211_bib225","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111465","article-title":"Complementary role of oxytocin and vasopressin in cardiovascular regulation","volume":"22","author":"Szczepanska-Sadowska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib226","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00213-006-0545-6","article-title":"Effect of paroxetine on enhanced contextual fear induced by single prolonged stress in rats","volume":"189","author":"Takahashi","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib227","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0022-3565(24)38047-4","article-title":"Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate","volume":"288","author":"Taverna","year":"1999","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"7","key":"10.1016\/j.neuropharm.2022.109211_bib228","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.biopsych.2005.09.023","article-title":"Daytime prazosin reduces psychological distress to trauma specific cues in civilian trauma posttraumatic stress disorder","volume":"59","author":"Taylor","year":"2006","journal-title":"Biol. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib229","doi-asserted-by":"crossref","DOI":"10.1080\/20008198.2020.1733248","article-title":"Trauma reactivation under propranolol among traumatized Syrian refugee children: preliminary evidence regarding efficacy","volume":"11","author":"Thierree","year":"2020","journal-title":"Eur. J. Psychotraumatol."},{"issue":"7","key":"10.1016\/j.neuropharm.2022.109211_bib230","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.biopsych.2021.07.009","article-title":"Failure of losartan in a clinical trial for posttraumatic stress disorder: lack of efficacy or spotlight on the power of placebo?","volume":"90","author":"Torregrossa","year":"2021","journal-title":"Biol. Psychiatr."},{"issue":"11","key":"10.1016\/j.neuropharm.2022.109211_bib231","doi-asserted-by":"crossref","first-page":"860","DOI":"10.4088\/JCP.v62n1105","article-title":"Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial","volume":"62","author":"Tucker","year":"2001","journal-title":"J. Clin. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib232","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4088\/JCP.v68n0204","article-title":"Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study","volume":"68","author":"Tucker","year":"2007","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109211_bib233","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172763","article-title":"Co-treatment of piracetam with risperidone rescued extinction deficits in experimental paradigms of post-traumatic stress disorder by restoring the physiological alterations in cortex and hippocampus","volume":"185","author":"Uniyal","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109211_bib234","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0079-6123(07)67014-9","article-title":"Models of PTSD and traumatic stress: the importance of research \"from bedside to bench to bedside","volume":"167","author":"Ursano","year":"2008","journal-title":"Prog. Brain Res."},{"issue":"9","key":"10.1016\/j.neuropharm.2022.109211_bib235","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0006-3223(03)00412-8","article-title":"Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma","volume":"54","author":"Vaiva","year":"2003","journal-title":"Biol. Psychiatr."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109211_bib236","first-page":"517","article-title":"Fluoxetine in posttraumatic stress disorder","volume":"55","author":"van der Kolk","year":"1994","journal-title":"J. Clin. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109211_bib237","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jts.22251","article-title":"Topiramate as monotherapy or adjunctive treatment for posttraumatic stress disorder: a meta-analysis","volume":"31","author":"Varma","year":"2018","journal-title":"J. Trauma Stress"},{"key":"10.1016\/j.neuropharm.2022.109211_bib238","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1196\/annals.1364.014","article-title":"Alterations in stress reactivity after long-term treatment with paroxetine in women with posttraumatic stress disorder","volume":"1071","author":"Vermetten","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib239","doi-asserted-by":"crossref","first-page":"245","DOI":"10.24869\/psyd.2022.245","article-title":"Quetiapine add-on therapy may improve persistent sleep disturbances in patients with PTSD on stabile combined SSRI and benzodiazepine combination: a one-group pretest-posttest study","volume":"34","author":"Vilibi\u0107","year":"2022","journal-title":"Psychiatr. Danub."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109211_bib240","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2016.15070967","article-title":"Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial","volume":"173","author":"Villarreal","year":"2016","journal-title":"Am. J. Psychiatr."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib241","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41401-018-0032-8","article-title":"Cannabidiol does not display drug abuse potential in mice behavior","volume":"40","author":"Viudez-Martinez","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib242","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/jts.22807","article-title":"Gender differences in disorders comorbid with posttraumatic stress disorder among U.S. Sailors and Marines","volume":"35","author":"Walter","year":"2022","journal-title":"J. Trauma Stress"},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib243","doi-asserted-by":"crossref","first-page":"263","DOI":"10.33549\/physiolres.931756","article-title":"Quetiapine ameliorates anxiety-like behavior and cognitive impairments in stressed rats: implications for the treatment of posttraumatic stress disorder","volume":"59","author":"Wang","year":"2010","journal-title":"Physiol. Res."},{"key":"10.1016\/j.neuropharm.2022.109211_bib244","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neulet.2015.08.017","article-title":"Preventive effects of ginsenoside Rg1 on post-traumatic stress disorder (PTSD)-like behavior in male C57\/B6 mice","volume":"605","author":"Wang","year":"2015","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib245","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0920-1211(97)00045-4","article-title":"Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold","volume":"28","author":"White","year":"1997","journal-title":"Epilepsy Res."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2022.109211_bib246","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1111\/j.1528-1157.2000.tb02165.x","article-title":"Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism","volume":"41","author":"White","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109211_bib247","first-page":"CD002795","article-title":"Pharmacotherapy for post traumatic stress disorder (PTSD)","volume":"3","author":"Williams","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2022.109211_bib248","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fnbeh.2014.00256","article-title":"Differential effects of sertraline in a predator exposure animal model of post-traumatic stress disorder","volume":"8","author":"Wilson","year":"2014","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109211_bib249","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bbr.2014.03.029","article-title":"Valproic acid effects in the hippocampus and prefrontal cortex in an animal model of post-traumatic stress disorder","volume":"268","author":"Wilson","year":"2014","journal-title":"Behav. Brain Res."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109211_bib250","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1523\/JNEUROSCI.3432-03.2004","article-title":"Oxytocin attenuates stress-induced c-fos mRNA expression in specific forebrain regions associated with modulation of hypothalamo-pituitary-adrenal activity","volume":"24","author":"Windle","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109211_bib251","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.psychres.2018.08.118","article-title":"The anxiolytic-like effects of estazolam on a PTSD animal model","volume":"269","author":"Xu","year":"2018","journal-title":"Psychiatr. Res."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109211_bib252","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1755-5949.2010.00188.x","article-title":"A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD","volume":"17","author":"Yeh","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuropharm.2022.109211_bib253","article-title":"Post-traumatic stress disorder","volume":"1","author":"Yehuda","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.neuropharm.2022.109211_bib254","series-title":"Propranolol for Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness","author":"Young","year":"2020"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib255","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/YIC.0b013e328352ef4e","article-title":"An open-label pilot study of aripiprazole for male and female veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants","volume":"27","author":"Youssef","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109211_bib256","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2019.101248","article-title":"Comparative efficacy of imagery rehearsal therapy and prazosin in the treatment of trauma-related nightmares in adults: a meta-analysis of randomized controlled trials","volume":"50","author":"Yucel","year":"2020","journal-title":"Sleep Med. Rev."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib257","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00213-014-3697-9","article-title":"Anxiolytic effects of ketamine in animal models of posttraumatic stress disorder","volume":"232","author":"Zhang","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109211_bib258","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.sleep.2019.06.010","article-title":"The effects of prazosin on sleep disturbances in post-traumatic stress disorder: a systematic review and meta-analysis","volume":"67","author":"Zhang","year":"2020","journal-title":"Sleep Med."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109211_bib259","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.905","article-title":"Propranolol can induce PTSD-like memory impairments in rats","volume":"8","author":"Zhu","year":"2018","journal-title":"Brain Behav"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib260","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4088\/JCP.v61n0310","article-title":"Nefazodone in patients with treatment-refractory posttraumatic stress disorder","volume":"61","author":"Zisook","year":"2000","journal-title":"J. Clin. Psychiatr."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109211_bib261","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1176\/appi.ajp.2018.17090995","article-title":"Doubly randomized preference trial of prolonged exposure versus sertraline for treatment of PTSD","volume":"176","author":"Zoellner","year":"2019","journal-title":"Am. J. Psychiatr."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109211_bib262","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0304-3940(97)00543-0","article-title":"Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells","volume":"231","author":"Zona","year":"1997","journal-title":"Neurosci. Lett."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:19:27Z","timestamp":1758439167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822002702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":262,"alternative-id":["S0028390822002702"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109211","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological strategies for post-traumatic stress disorder (PTSD): From animal to clinical studies","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109211"}}